Immune System Modulation: BPC-157 exhibits immunomodulatory properties by regulating immune responses and modulating the activity of immune cells
For hematocrit and reticulocyte counts, recommendations are to repeat these tests daily from the 5th to 7th days of treatment and then frequently until the hematocrit returns to a normal range (11, 14, 15)
Both flagged some examples as posing potential legal risks, under statutes that limit the claims health care providers can make about drugs that are not FDA-approved
10mg vial add 2.5mL (4mg/mL)
The announcement was widely interpreted as a signal that the FDA under the new administration would take a more permissive stance toward peptide compounding than the 2023 Pharmacy Compounding Advisory Committee position, which had placed BPC-157 firmly in Category 2 (substances the FDA had concerns about for compounding use)
Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, et al